Cagrilintide: doses reported in published research

Sources checked 2026-10-07 · 2 cited studies (2 human, 0 animal, 0 cell culture)

Cagrilintide is an investigational long-acting amylin analogue (an amylin-receptor agonist, often grouped with GLP-class weight-management compounds and studied together with semaglutide). It is not approved by the FDA; doses below come from published phase 1b and phase 2 trials.

Human data: published phase 1b and phase 2 trials.

Studies in people (2)

Human Adults with BMI 30 or more (or 27 or more with hypertension or dyslipidaemia), without diabetes; phase 2 dose-finding randomized trial (706 on cagrilintide)

Dose as reported: 0.3, 0.6, 1.2, 2.4 or 4.5 mg (separate groups)
Route: Subcutaneous
Frequency / duration: Once weekly for 26 weeks, including up to 6 weeks of dose escalation

Source wording: Participants were randomly assigned (6:1) to subcutaneous self-injections of once-weekly cagrilintide (0·3, 0·6, 1·2, 2·4, or 4·5 mg), once-daily liraglutide 3·0 mg, or volume-matched placebo The trial had a 26-week treatment period, including a dose-escalation period of up to 6 weeks we randomly assigned 706 participants

Lau DCW, Erichsen L, Francisco AM et al.. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021. PubMed PMID 34798060 ↗

Human Adults (96 randomized), phase 1b trial of cagrilintide together with semaglutide 2.4 mg

Dose as reported: 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg (sequential cohorts), each with semaglutide 2.4 mg
Route: Subcutaneous
Frequency / duration: Once weekly (week-20 results reported)

Source wording: randomly assigned (3:1) to once-weekly subcutaneous cagrilintide (0·16, 0·30, 0·60, 1·2, 2·4, or 4·5 mg) or matched placebo, in combination with once-weekly subcutaneous semaglutide 2·4 mg 96 were randomly assigned At week 20

Enebo LB, Berthelsen KK, Kankam M et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PubMed PMID 33894838 ↗

Half-life

Human 159-195 h (cagrilintide 0.16-4.5 mg with semaglutide 2.4 mg, phase 1b). Source wording: Cagrilintide 0·16-4·5 mg had a half-life of 159-195 h, with a median tmax of 24-72 h. in combination with once-weekly subcutaneous semaglutide 2·4 mg
Enebo LB, Berthelsen KK, Kankam M et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 2021. PubMed PMID 33894838 ↗

About this page

Every figure above is copied from the cited source; the source wording is shown with each entry. Where a source does not state something, the page says so.
Only abstracts, open-access full texts, registry records and FDA labels were used, so details found only in a paywalled full text may be missing.
This page does not convert doses between species or into other measures, and gives no preparation or handling information.